Ovarian cancer is one of the common malignant tumors in gynecology with an insidious onset. Liver is the most common distant solid metastatic organ of advanced ovarian cancer (57%), followed by lung (38%), bone (4%) and brain (1%).
Ovarian cancer combined with liver metastasis can be treated, and with standardized treatment, patient survival can be prolonged and prognosis improved.
For resectable patients, surgical treatment, such as partial hepatectomy, peritoneal implant resection, and lymph node dissection, is usually recommended.
For unresectable patients, it includes chemotherapy (systemic and local), local ablation therapy, transarterial chemoembolization (TACE) and targeted therapy.
Some studies claim that the 1-year overall survival rate of ovarian cancer combined with liver metastasis is about 80%, and the 5-year overall survival rate is about 40%.
Patients with liver metastasis of ovarian cancer are recommended to go to regular hospitals for timely treatment to control the growth and development of the tumor, reduce the symptoms, prolong the survival period, improve the quality of life and improve the prognosis.